UBS AM
AVEO

UBS AM’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

UBS AM’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-4,390
Closed -$91K – 2574
2013
Q3 		$91K Hold
4,390
– – ﹤0.01% 2466
2013
Q2 		$110K Buy
+4,390
New +$188K ﹤0.01% 2392

Other funds holding AVEO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS AM's AVEO Position: Q4 2013 in Review

UBS AM sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2013, closing a stake of 4,390 shares — an estimated $91K sold.

UBS AM first reported a position in AVEO in Q2 2013 and held it in 2 quarters. The position peaked at $110K in Q2 2013. 70 funds tracked by Wall St. Rank hold AVEO as of Q4 2013.

  • UBS AM reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2013 after selling out during the quarter.
  • UBS AM sold 4,390 AVEO Pharmaceuticals, Inc. shares in Q4 2013, an estimated $91K.
  • UBS AM first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 2 quarters.
  • UBS AM's AVEO Pharmaceuticals, Inc. position peaked at $110K in Q2 2013.
  • 70 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2013.

Based on UBS AM's 13F filing for Q4 2013, filed 31 Jan 2014.